|
|
||||||||

* Ocular Immunology Group, Schepens Eye Research Institute, Harvard Medical School, Boston, MA 02114; and
Division of Pulmonary and Critical Care, Department of Medicine, Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02115
| Abstract |
|---|
|
|
|---|
18-deficient mice (lacking invariant NKT) to develop peripheral tolerance postintracameral inoculation of Ag. Also, we were able to induce peripheral tolerance directly in IL-13-deficient, IL-4/IL-13-double deficient, and STAT6-deficient mice by inoculation of Ag into their eye. We conclude that neither IL-4 nor IL-13 cytokines are required for the generation of efferent CD8+ T regulatory cells during eye-induced peripheral tolerance. We propose that Ags inoculated into the anterior chamber of the eye induce the immunoresponse to deviate from producing immune T effector cells to producing efferent T regulatory cells, rather than deviating from Th1- to Th2-type effector cells. | Introduction |
|---|
|
|
|---|
TGF-
is an essential cytokine needed in the generation of Tr cells in ACAID (9, 10). The need for Ag inoculation into the eye for tolerance induction can be bypassed, by i.v. injection of TGF-
-treated, Ag-pulsed APC (tolerogenic APC) into naive syngeneic recipients and the subsequent generation of CD8+ Tr cells capable of suppressing DTH responses (7). Addition of anti-TGF-
mAb to peritoneal exudate cell (PEC) cultured in aqueous humor abolishes the ability of aqueous humor-cultured PEC to induce ACAID or to generate CD8+ Tr in recipients (9, 10). In fact, TGF-
treatment and Ag exposure of a variety of APC populations produce a semi-mature APC that induces most, if not all, aspects of peripheral tolerance induced by Ag inoculation into the eye.
TGF-
, IL-10, IL-4, and IL-13 are all capable of interacting to down-regulate immune responses. TGF-
is produced by various types of cells and usually secreted in latent form (11). Both IL-10 and IL-13 are reported to induce secretion and activation of TGF-
. IL-10 induces TGF-
secretion by Tr cells in a mouse model of experimental colitis (12). IL-12 and IFN-
inhibit TGF-
production of CD4+ T cells, whereas IL-10 enhances TGF-
production by indirectly effecting IL-12 secretion (and production) (13). Activated immune cells show reduced TGF-
2 receptor expression, but IL-10 reverses the down-regulation (14). IL-13 is reported to stimulate production of active TGF-
in a pulmonary fibrosis model (15). Furthermore, IL-4 and IL-13 down-regulate IFN-
production and thus prevent the interference with intracellular TGF-
signaling by IFN-
-dependent SMAD-7 production (16). More recently, it was reported that tumor effector cells could be generated in STAT6-deficient mice but not in IL-4
receptor-deficient mice, implicating a role for IL-13-dependent immunosuppression in tumor growth (17).
These conflicting reports suggest a need to clarify the role of Th2 cytokines in ACAID. The focus of this investigation was to evaluate the contribution of the Th2 cytokine, IL-13, in generating CD8+ Tr cells in ACAID. Moreover, in another model of tumor immunosuppression, IL-13-producing NKT cells regulate anti-tumor immunity (18, 19). Interestingly, iNKT cells are important in both the tumor recurrence model and ACAID, and both models can be induced in IL-4-deficient mice (4, 5, 7, 18). Thus, because iNKT cells are central to the development of ACAID (4, 5), we postulated that perhaps NKT cell-derived IL-13 might be required for the generation of the Ag-specific efferent CD8+ Tr cells known to suppress CD4+ effector T cells (20).
| Materials and Methods |
|---|
|
|
|---|
Female BALB/c mice were purchased from Taconic Farms; IL-13/ and IL-4//IL-13/ mouse breeders were generous gifts from A. McKenzie, University of Oxford (Oxford, U.K.). IL-13/ mice were generated from 129 x C57BL/6 mice, with the disruption in exon 1 (21), and were backcrossed for seven generations onto the BALB/c strain. IL-4//IL-13/ mice were generated from 129 x C57BL/6 mice (22) and backcrossed for seven generations onto the BALB/c strain. STAT6/ mice on C129.S2 background and WT controls were obtained from The Jackson Laboratory. J
281/ (BALB/c background) mice were bred in the Schepens vivarium from breeders that were a generous gift from M. Taniguchi (Chiba University Graduate School of Medicine, Chiba, Japan). Mice were housed on a 12:12-h light-dark cycle and provided food and water ad libitum. All animals were treated humanely and in accordance with the guidelines set forth by the Schepens Eye Research Institute Animal Care and Use Committee and National Institutes of Health guidelines.
Peripheral tolerance induction via the eye and assay for DTH
Peripheral tolerance was induced as previously described (23). In brief, 2 µl of OVA (50 µg) in PBS were inoculated into the a.c. of the eye using a specially prepared glass needle. One week later, mice were immunized (s.c.) with OVA (100 µg/50 µl in HBSS) emulsified in CFA (50 µl). To test for DTH, OVA (200 µg in 10 µl PBS) was inoculated into the ear pinnae 1 wk after immunization, and ear swelling was measured 24 h later with an engineers micrometer (Mitsutoyo).
Reconstitution of J
281/ mice and ACAID induction
To reconstitute the iNKT cells deficiency in J
281/ mice, J
281/ mice were gamma-irradiated (cesium, 200 rad, Mark 1 irradiator; J. L. Shepherd) 24 h before they received (i.v.) pan-T cell IMMULAN column-enriched spleen cells (107) from either WT, IL-13/, or IL-4//IL-13/ mice. Twenty-four hours after reconstitution, J
281/ mice were inoculated (a.c.) with OVA (50 µg/2 µl in PBS) to generate Ag-specific CD8+ Tr cells.
Local adoptive transfer (LAT) assay
To assess the development of efferent regulatory cell function, a modified LAT assay was performed (23). In brief, effector cells were generated in WT BALB/c mice immunized (s.c.) with OVA (100 µg, 1:1 HBSS:CFA). Ten days later, effector T cells were enriched using pan-T cell IMMULAN columns (Biotecx Laboratories). Naive T cells from unmanipulated mice were used as effector cells for the negative control group. Regulator cells were similarly enriched on pan-T cell IMMULAN columns from spleen cells of mice 7 days after a.c. inoculation of OVA. Stimulator cells were prepared by pulsing thioglycolate-induced PEC (106/ml) with OVA (5 mg/ml). Effector cells (5 x 105), stimulator cells (2 x 105), and Tr cells (5 x 105) were admixed and resuspended in 10 µl of HBSS and inoculated into the ear pinnae of naive B6 mice. Ear thickness was measured with an engineers micrometer at 24 h. Splenic T cells from unmanipulated mice were used as regulatory cells for positive control.
Statistics
Data were analyzed by ANOVA and Scheffes test. A value of p
0.05 was considered significant.
| Results |
|---|
|
|
|---|
18-deficient mice
Based on the role of NKT cell-derived IL-13 in a tumor model of suppression, we tested whether NKT cell-derived IL-13 played a role in ACAID (18). It is known that J
18/ mice are unable to develop peripheral tolerance post-eye inoculation of Ag, unless they are reconstituted with NKT cells from WT mice (4). To test the hypotheses that IL-13 derived from NKT cells was required for peripheral tolerance induction, J
18/ mice were reconstituted with T cell-enriched spleen cells (pan-T cell Immulan column passed) from WT, IL-13/, or IL-4//IL-13/ mice, and their efferent Tr cell function was assessed in a LAT assay (Fig. 1). T cells from nonreconstituted J
18/ mice were unable to suppress DTH ear swelling, but T cells harvested from J
18/ mice that were reconstituted with IMMULAN-enriched T cells from WT, IL-13/, or IL-4//IL-13/ mice suppressed the adoptively transferred DTH response. Because the J
18/ mice are only missing the iNKT cell population, we felt that a mixed T cell population was better to use for reconstitution than an enriched NKT cell population, which might be altered by Ab binding and the sorting process.
|
Because J
18/ mice do have cells that are capable of producing IL-13, we tested whether IL-13 derived from non-NKT cells were important for tolerance development in IL-13/ mice. We reasoned that if IL-13 were important for eye-induced peripheral tolerance, we would not be able to induce ACAID in IL-13/ mice. In brief, IL-13/ mice were inoculated (a.c.) with OVA 7 days before sensitization (s.c.) with OVA and CFA and 14 days before ear challenge with the Ag. The DTH response was suppressed (evidence of peripheral tolerance) in the IL-13-deficient mice, indicating that there is no requirement for IL-13 in the generation of the efferent Tr cell responsible for diminishing ear swelling (Fig. 2).
|
STAT6/ mice developed peripheral tolerance via the eye
To further confirm the independence of eye-induced peripheral tolerance from either IL-4 or IL-13 signals, STAT6/ mice were tested for their susceptibility to peripheral tolerance induction by a.c. inoculation of Ag (Fig. 3). Similar to results with IL-4/ on IL-13/ mice, a.c. inoculation of STAT6/ mice induced tolerance to the Ag, and ear challenge of the mice with Ag showed a significant suppression of Ag-induced DTH compared with non-a.c.-inoculated mice. This result confirms our postulate that induction of peripheral tolerance via the eye is not dependent on signals derived through the IL-4
or the IL-13
receptors because both of these receptors use STAT6 in their pathway.
|
| Discussion |
|---|
|
|
|---|
However, conflicting data was also reported, because peripheral tolerance was induced in IL-4/ mice post-a.c. inoculation of Ag (7), and, later, Katagiri et al. (6) showed that both ACAID induction and ACAID-like tolerogenic APC (generated in vitro by exposure of PEC to TGF-
and Ag) were able to down-regulate Th2 responses in a lung model of airway hyperreactivity and inflammation in the mouse. Also contradictory to Th2 cells being involved in ACAID is our report that conventional CD4+ T cells are not needed for the generation of CD8+ Tr cells (30). In that study, we showed that intracameral inoculation of Ag induces peripheral tolerance and CD8+ Tr cells into the eye of class II-deficient mice (which lack conventional CD4+ T cells) (30). Thus CD4+ Th cells are not needed for the generation of the efferent CD8+ Tr cell in ACAID. Alternatively, although IL-4 is predominately made by CD4+ T cells, IL-13 could still be produced in class II-deficient mice by many cell types, thus allowing for the possibility that select Th2 cytokines contribute to ACAID. A report by Terabe et al. stimulated our interest when it showed that, in a mouse model of tumor recurrence, NKT cell-derived IL-13 was a major contributor to the tolerance (18) of the tumor. However, we show in this study that IL-13 has no role in the development of efferent Tr cells and peripheral tolerance in ACAID.
IL-4 and IL-13 operate through the IL-4 and IL-13 receptors, respectively. Both receptors share the
-chain of the IL-4 receptor (31, 32) and promote the STAT6 factor for activation (33). Contact hypersensitivity to various allergens is reduced in STAT6/ mice, whereas DTH reaction to sheep RBC is maintained (34). IL-13 is associated with the stimulation of TGF-
production in the development of fibrosis (15). Because neither IL-13 nor STAT6 is required for generation of CD8+ Tr cells in peripheral tolerance induced in the eye, the other mechanisms known for stimulating and activating TGF-
, including thrombospondin (35) and IL-10 (15), may be sufficient.
There are mechanistic differences between the tumor tolerance model and peripheral tolerance related to a.c. inoculation. Unlike peripheral tolerance induced in the eye, iNKT cell-derived IL-13 activates Gr1+Cd11b+ myeloid-derived suppressor cells, which in turn produce immunosuppressive TGF-
(19). The role of iNKT cells in eye-induced peripheral tolerance is that they appear to facilitate cellular interactions within the MZ of the spleen where CD8+ Tr cells are generated. The efferent CD8+ Tr cell suppresses immune effector cells (24) in an Ag-specific fashion. There is some evidence that the iNKT cells promote the recruitment of cells to the MZ of the spleen (36), as well as create a tolerance-inducing environment by secreting immunosuppressive factors (37, 38).
In conclusion, our data suggest that IL-4, IL-13, and STAT6 are not needed for the generation of Ag-specific efferent CD8+ Tr cells. Together with the fact that conventional CD4+ T cells are also not needed (30), these data strongly contradict the notion that inoculation of Ag into the eye induces a deviation from Th1- to Th2-type cytokines. In fact, we show here that Th2 cytokines and their signaling pathways are not involved in the generation of the efferent CD8+ Tr cell in eye-induced peripheral tolerance. These data do not contradict the fact that intracameral inoculation of Ag induces an immune deviation but rather more precisely define the deviation from immune T effector cells to Tr cells.
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported in part by National Institutes of Health Grants R01 EY11983 and EY13066 (to J.S.-S.) and by the Schepens Eye Research Institute. ![]()
2 Current address: Department of Opthalmology, Graduate School of Medicine Science, Kyushu University, Fukuoka, Japan ![]()
3 Address correspondence and reprint requests to Dr. Joan Stein-Streilein, Schepens Eye Research Institute, 20 Staniford Street, Boston, MA 02114. E-mail address: jstein{at}vision.eri.harvard.edu ![]()
4 Abbreviations used in this paper: MZ, marginal zone; a.c., anterior chamber; ACAID, anterior chamber-associated immune deviation; DTH, delayed-type hypersensitivity; iNKT, invariant NKT; LAT, local adoptive transfer; PEC, peritoneal exudate cell; Te, T effector; Tr, T regulatory; WT, wild type. ![]()
Received for publication February 7, 2005. Accepted for publication May 16, 2005.
| References |
|---|
|
|
|---|
and induction of TGF-
and IL-4 production. J. Immunol. 161: 5382-5390.
. Eur. J. Immunol. 22: 165-173. [Medline]
. Eur. J. Immunol. 22: 1031-1036. [Medline]
. J. Cell Biol. 105: 965-975.
and IL-10 in the regulation of experimental colitis. J. Immunol. 168: 900-908.
-producing cells from naive CD4+ T cells: IL-4 and IFN-
have opposing effects, while TGF-
positively regulates its own production. J. Immunol. 160: 5719-5728.
response during T cell activation is modulated by IL-10. J. Immunol. 167: 773-778.
1. J. Exp. Med. 194: 809-821.
/SMAD signalling by the interferon-
/STAT pathway. Nature 397: 710-713. [Medline]
production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198: 1741-1752.
-treated APCs and its relevance to their immune deviation-promoting properties. J. Immunol. 168: 2264-2273.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |